← Browse by Condition
Medical Condition

paroxysmal nocturnal hemoglobinuria pnh

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for paroxysmal nocturnal hemoglobinuria pnh sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — paroxysmal nocturnal hemoglobinuria pnh Clinical Trials

How many clinical trials are currently recruiting for paroxysmal nocturnal hemoglobinuria pnh?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for paroxysmal nocturnal hemoglobinuria pnh, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for paroxysmal nocturnal hemoglobinuria pnh?
paroxysmal nocturnal hemoglobinuria pnh research spans Phase 1 (3 trials), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a paroxysmal nocturnal hemoglobinuria pnh clinical trial?
Eligibility criteria for paroxysmal nocturnal hemoglobinuria pnh trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
1
Top Sponsors
Haisco Pharmaceutical Group Co., Ltd. 1 trial
Apellis Pharmaceuticals, Inc. 1 trial
Shenzhen Kangzhe Biotechnology Co., Ltd. 1 trial
Zhuhai United Laboratories Co., Ltd. 1 trial

Recruiting Clinical Trials

NCT07152288 Phase 1
Recruiting
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment
Enrollment
24 pts
Location
China
Sponsor
Haisco Pharmaceutical Group Co...
View Trial →
NCT04901936 Phase 2
Recruiting
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Enrollment
12 pts
Location
United States, Czech...
Sponsor
Apellis Pharmaceuticals, Inc.
View Trial →
NCT07462780 Phase 1
Recruiting
A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants
Enrollment
88 pts
Location
China
Sponsor
Shenzhen Kangzhe Biotechnology...
View Trial →
NCT07760467 Phase 1
Recruiting
To Evaluate Safety, Tolerability, PK/PD & Food Effect of Single/Multiple Oral TUL321 Capsules in Healthy Participants.
Enrollment
94 pts
Location
China
Sponsor
Zhuhai United Laboratories Co....
View Trial →

Related Conditions

paroxysmal hemoglobinuria (1) complement mediated kidney disease (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology